News

Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia

rows of pills on transparent background

blue and white pill

blue and white pill

blue and white pill

blue and white pill

WELCOME TO LYNDRA THERAPEUTICS

Medicine, reinvented

Medicine

, reinvented

rows of pills on transparent background

blue and white pill

blue and white pill

blue and white pill

blue and white pill

Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra’s LYNX^® drug delivery platform has the potential for broad applicability across multiple therapeutic areas – including approved drugs and those currently in development.

Freedom from daily pills

Pioneering long-acting oral therapies

Helping Patients

The LYNX^® drug delivery platform is designed to transform the patient experience, freeing people from the burden of daily pills and simplifying their lives.

The team to reinvent medicine

Lyndra’s visionary and determined team continues to break barriers in the quest to launch one of the most significant oral drug delivery innovations in decades.

The Lyndra Story

Lyndra’s story began in 2015 with technology that emerged from the Langer Lab at MIT. Today, Lyndra is getting closer to bringing long-acting oral therapies to people living with a wide range of health conditions.

Lyndra’s culture advantage

Lyndra’s core purpose to reinvent medicine for a healthier world, coupled with its unique values and the exceptional people who live them every day, make Lyndra a distinctive company with the culture, purpose and drive to succeed. 

Inspired by innovation and growth

The members of the Lyndra team are engineers and designers, technologists and chemists, doctors and nurses, and people of many other backgrounds who have all come together to reinvent medicine. Does Lyndra sound like a great fit for you? Come join the team!

The Lyndra Story

Lyndra’s story began in 2015 with technology that emerged from the Langer Lab at MIT. Today, Lyndra is getting closer to bringing long-acting oral therapies to people living with a wide range of health conditions.

Lyndra’s culture advantage

Lyndra’s core purpose to reinvent medicine for a healthier world, coupled with its unique values and the exceptional people who live them every day, make Lyndra a distinctive company with the culture, purpose and drive to succeed. 

Inspired by innovation and growth

The members of the Lyndra team are engineers and designers, technologists and chemists, doctors and nurses, and people of many other backgrounds who have all come together to reinvent medicine. Does Lyndra sound like a great fit for you? Come join the team!

News

elderly woman looking out the window

January 4, 2024

Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia

December 21, 2023

Lyndra Therapeutics Raises $101 Million in Series E Funding

July 17, 2023

Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress

May 31, 2023

Lyndra Therapeutics Presents Data on Long-Acting Oral Weekly Risperidone (LYN-005) at American Society of Clinical Psychopharmacology 2023 Annual Conference

May 9, 2023

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder

January 5, 2023

Lyndra Therapeutics Announces New Board Members and Chief Technology Officer

View All News